PharmaDrug receives encouraging potency data for candidate DMT-analogue molecules designed to treat primary open angle glaucoma Terasaki Institute advances PharmaDrug’s candidate DMT-analogue molecules into next phase of potency/kinetics study Terasaki Institute initiates fabrication of novel medical device designed to deliver PharmaDrug’s lead candidate to glaucoma patients Toronto…
